Journal
FRONTIERS IN IMMUNOLOGY
Volume 11, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2020.613830
Keywords
immunotherapy; vaccine; cancer; immune; polyplex; nanoparticle; co-delivery; self-assembly
Categories
Funding
- NIH [R01 EB027143]
- United States Department of Veterans Affairs [I01 BX003690]
Ask authors/readers for more resources
The study demonstrates the development of polyplex-like nanoparticles using a conserved human melanoma peptide antigen modified with cationic arginine residues and an anionic toll-like receptor agonist CpG. These nanoparticles offer tunable loading and improvement in antigen uptake by primary antigen presenting cells, enhancing the functionality of specific T cells and decreasing tumor burden in a mouse melanoma model. The research highlights the potential of controlling biophysical properties of nanostructured materials to enhance immunotherapy without the complexity associated with synthetic carriers.
Biomaterial delivery systems offer unique potential to improve cancer vaccines by offering targeted delivery and modularity to address disease heterogeneity. Here, we develop a simple platform using a conserved human melanoma peptide antigen (Trp2) modified with cationic arginine residues that condenses an anionic toll-like receptor agonist (TLRa), CpG, into polyplex-like nanoparticles. We reasoned that these structures could offer several useful features for immunotherapy - such as tunable loading, co-delivery of immune cues, and cargo protection - while eliminating the need for synthetic polymers or other complicating delivery systems. We demonstrate that Trp2/CpG polyplexes can readily form over a range of Trp2:CpG ratios and improve antigen uptake by primary antigen presenting cells. We show antigen loading can be tuned by interchanging Trp2 peptides with defined charges and numbers of arginine residues. Notably, these polyplexes with greater antigen loading enhance the functionality of Trp-2 specific T cells and in a mouse melanoma model, decrease tumor burden and improve survival. This work highlights opportunities to control the biophysical properties of nanostructured materials built from immune signals to enhance immunotherapy, without the added complexity or background immune effects often associated with synthetic carriers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available